InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector Expands rare cannabinoid portfolio beyond current CBC and CBTReleases White Paper outlining research into the therapeutic potential of CBDV VANCOUVER, British Columbia and SOUTH SAN FRANCISCO,...

InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCVExpands the Company’s rare cannabinoid product portfolio, which also includes...